BPC-157 Chitosan Hydrogel Research: Study Findings

A newly published study in the peer-reviewed journal 3 Biotech has taken a significant step toward expanding how BPC-157, a well-researched peptide, might be delivered in clinical and biomedical settings. Researchers fabricated and characterized a composite hydrogel combining BPC-157 with chitosan — a naturally derived biopolymer — and evaluated its physicochemical and antibacterial properties. The findings, published in August 2026, suggest this formulation may hold meaningful potential as a multifunctional delivery system, though the authors note that further investigation, including human clinical data, will be needed to validate these preliminary results (Arunim, Dagar M, Solanki M, et al., 2026).

What This Study Found

The research team fabricated a chitosan/BPC-157 composite hydrogel — referred to throughout the study as CH/BPC — and subjected it to a comprehensive battery of physicochemical analyses to evaluate its suitability for biomedical applications.

Structural Characterization: Using scanning electron microscopy (SEM) and transmission electron microscopy (TEM), researchers confirmed that the hydrogel exhibited a porous internal structure. Porous architectures in hydrogels are generally considered advantageous for biomedical applications, as they can facilitate nutrient and fluid exchange and support controlled release of encapsulated agents.

Peptide Integration: Fourier-transform infrared spectroscopy (FTIR) analysis revealed the presence of hydrogen bonding between the BPC-157 peptide and the chitosan backbone. Researchers interpreted this as evidence of successful peptide incorporation within the hydrogel matrix — a critical finding for ensuring that the active compound remains structurally intact and potentially bioavailable within the delivery system.

Encapsulation and Release Profile: One of the more notable findings of the study was the hydrogel's encapsulation efficiency of 98.9 ± 0.8% for BPC-157. This near-complete encapsulation suggests the formulation was highly effective at retaining the peptide within the matrix. The hydrogel demonstrated a controlled release profile, with 81.2 ± 2.9% of the encapsulated BPC-157 released within 24 hours — a release kinetic that researchers suggest may be relevant for sustained local delivery applications.

Physical and Mechanical Properties: The CH/BPC hydrogel demonstrated a balanced water vapor transmission rate of 2,270 ± 35 g/m²/day, along with injectability, self-healing capability, and adhesiveness. These mechanical characteristics are particularly relevant for wound care and tissue engineering applications, where a material must conform to irregular surfaces and maintain integrity over time.

Antibacterial Activity: The composite hydrogel demonstrated antibacterial efficacy against two common pathogenic bacteria. Against Escherichia coli, the hydrogel achieved up to 45.9% inhibition, while against Staphylococcus aureus, inhibition reached 65.0%. Both of these bacteria are frequently implicated in wound infections, making this finding particularly relevant to potential wound-care applications.

Hemocompatibility: Safety evaluation of the hydrogel included a hemolysis assay, which measures the degree to which a material causes red blood cell rupture upon contact. The CH/BPC hydrogel demonstrated a hemolysis rate of less than 5%, which the authors indicate falls within the threshold considered acceptable for hemocompatible biomaterials.

Clinical Significance

It is important to note that this research was conducted as a materials characterization study — it did not involve animal models or human subjects. As such, the findings should be understood as foundational, proof-of-concept work that establishes the physicochemical viability of the CH/BPC hydrogel. Human clinical data will be necessary before any therapeutic applications can be claimed or established.

That said, the study's findings are scientifically meaningful within the broader context of peptide delivery research. BPC-157 has been studied in preclinical settings for its potential roles in tissue repair, angiogenesis, and inflammatory modulation. A persistent challenge in peptide therapeutics is ensuring bioavailability and protecting peptides from degradation prior to reaching their target tissue. A hydrogel delivery system with near-complete encapsulation efficiency and a defined release profile represents a potentially important advance in addressing this challenge.

Furthermore, the dual functionality of the CH/BPC hydrogel — offering both peptide delivery and intrinsic antibacterial activity — is a particularly compelling characteristic from a biomedical design standpoint. Multifunctional materials that can simultaneously protect against infection and deliver a therapeutic agent are increasingly sought after in fields such as wound management, surgical applications, and regenerative medicine.

Chitosan itself has a well-established safety profile in biomedical research and is derived from chitin, a naturally occurring polymer found in crustacean shells. Its inherent biocompatibility and biodegradability make it a widely studied candidate for drug delivery scaffolds, lending additional scientific rationale to its use as the hydrogel backbone in this study.

Current Access and Compliance Context

BPC-157 is a synthetic peptide that remains in investigational status in most regulatory jurisdictions, including the United States, where it is not approved by the FDA for any therapeutic indication. It is currently used in research contexts and, in some cases, prescribed by licensed physicians under compounding pharmacy frameworks, though regulatory landscapes are evolving.

Patients and practitioners should be aware that compounded peptide formulations are subject to varying regulatory oversight depending on jurisdiction. Additionally, the specific CH/BPC hydrogel formulation described in this study is a research-stage material and is not currently available as a commercial product. The study represents early-phase materials science research that, if followed by appropriate preclinical and clinical investigation, could eventually inform novel delivery methods for BPC-157 or similar peptides.

Practitioners considering BPC-157 as part of a patient care protocol should consult current regulatory guidance and work only with appropriately licensed compounding pharmacies and within the full scope of their clinical training.

What Patients Should Know

For patients who are curious about BPC-157 or who have encountered information about it in wellness or regenerative medicine contexts, this study offers an important perspective: the science surrounding this peptide is actively developing, and researchers are working to optimize not only what it may do, but how it can be most effectively and safely delivered.

The development of a hydrogel delivery system with high encapsulation efficiency and antibacterial properties represents the kind of rigorous, methodical research that would need to underpin any future clinical application. However, patients should understand that this study does not establish that the CH/BPC hydrogel is ready for human use, nor does it prove therapeutic efficacy in any condition.

If you are interested in learning more about BPC-157 research and whether peptide-based therapies may be appropriate for your health goals, the most important first step is a consultation with a knowledgeable, licensed healthcare provider who specializes in this area. Self-administration of research-stage peptides outside of medical supervision carries risks that have not been fully characterized in the literature.

Conclusion

The 2026 study by Arunim, Dagar, Solanki, and colleagues represents a meaningful contribution to the growing body of research exploring innovative delivery systems for BPC-157. The CH/BPC composite hydrogel demonstrated high encapsulation efficiency, controlled release kinetics, antibacterial activity, and acceptable hemocompatibility in laboratory characterization studies. Researchers suggest these properties make it a promising candidate for further investigation as a multifunctional biomedical material.

As with all early-stage research, these findings require replication and progression through preclinical and eventually clinical studies before any conclusions about human therapeutic benefit can be drawn. Patients and practitioners are encouraged to follow the peer-reviewed literature and consult with qualified medical professionals when evaluating peptide-related therapies.

To connect with a physician who is knowledgeable about peptide research and evidence-based integrative medicine, visit peptideassociation.org/find-a-doctor.

---

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The content summarizes published research and should not be interpreted as an endorsement of any specific therapy, product, or clinical approach. Always consult a qualified and licensed healthcare provider before making any decisions about your health or treatment options. BPC-157 is not approved by the FDA for any therapeutic indication in the United States.

---

Citation (AMA Format):
Arunim, Dagar M, Solanki M, et al. Fabrication and characterization of biocompatible BPC-157 based chitosan hydrogel. 3 Biotech. 2026;[Epub ahead of print]. doi:10.1007/s13205-026-04951-4. PMID: 42555375.